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Introduction
Ovarian cancer is the fifth leading cause of cancer-related death in women in developed countries and has one of the highest ratios of incidence to death (1) . The standard postoperative chemotherapy for epithelial ovarian cancer is a combination therapy including Cisplatin and taxanes. Most patients are responsive to chemotherapy at first; however, toxicity and acquired resistance to Cisplatin have proven challenging and represent the major obstacle to improve the prognosis of patients with ovarian cancer (1) . Cisplatin resistance is due to a broad panel of molecular and functional alterations, including the reduced intracellular accumulation through the copper transporter 1 (Ctr1) and the increased efflux through the cell membrane (2) . Thus, the development of new Cisplatin formulations or the encapsulation into liposomes to overcome both resistance and toxicity remains a high priority (3).
While various formulations of Cisplatin encapsulated into liposomes demonstrated a good
anticancer activity in vitro, the results obtained in vivo were often disappointing (3) . One example is SPI-77, which did not produce significant clinical response rates in several Phase II studies of patients with inoperable head and neck cancer, advanced non-small-cell lung cancer (4) , and also in ovarian cancer (5) . The lack of therapeutic efficacy was likely due to slow and inefficient release of platinum from SPI-77.
Lipoplatin is one of the most promising liposomal platinum drug formulations under clinical investigation (3, 4, 6) . It has shown similar efficacy as Cisplatin in pancreatic, head and neck cancer, NSCLC and HER-2/neu-Negative Metastatic Breast Cancer with a major benefit of a strongly reduced toxicity (6, 7) . Author Manuscript Published OnlineFirst on September 17, 2014; DOI: 10.1158/1078-0432.CCR- Lipoplatin nanoparticles fuse with the cell membrane or are rapidly taken up by cancer cells by their avidity for nutrients, as shown with fluorescent nanoparticles, and Lipoplatin disguises as a nutrient with its lipid shell (6) . Thus the toxic payload enters the cytoplasm bypassing active import, explaining Lipoplatin's efficacy against platinum-resistant tumors (6) . Accordingly, we demonstrated that Lipoplatin is active both in vitro and in vivo against Cisplatin-resistant cervical cancer cells (8) . Lipoplatin has an enhanced half-life circulation time in body fluids and tissues and can extravasate through the leaky tumor vasculature reaching concentrations 10-to 200-fold higher in the tumor or metastases compared to the adjacent normal tissues. During their extravasation into primary and metastatic tumor tissue shown in human studies (9) Lipoplatin nanoparticles attack the epithelial cancer cells linked to the property of classic Cisplatin chemotherapy, but also the endothelial cells of tumor vasculature because of their lipid nature; thus Lipoplatin is acting as a chemotherapeutic and anti-angiogenesis drug (10) . The greater the vascularization of the tumor, the greater the concentration of Lipoplatin in the tumor or metastasis (9) .
Given the properties of Lipoplatin to overcome Cisplatin-resistance and to induce low toxicity (6, 8) , this drug could represent a good alternative to Cisplatin. The aim of our study was to analyze the efficacy of Lipoplatin in the ovarian cancer setting. Although many drugs show promising results in vitro, the success rate of anti-cancer therapies translating from in vitro culture systems into the clinic is about 5%, suggesting the use of multiple techniques during the preclinical evaluation of new anticancer agents. Thus, using the in vitro traditional two-dimensional (2D) model, the in vitro three-dimensional (3D) cell culture, that seems to better reflect the histological, biological, and molecular features of primary tumors (11) and CD133 (AC133, Miltenyi Biotec, Auburn, CA, USA.) were evaluated as previously described (8, 13) . Cell cycle was evaluated by PI staining. Aldehyde dehydrogenase (ALDH) activity was evaluated using Aldeflour reagent based method (Stem Cell Technologies, Vancouver, Canada). Briefly, cells (2×10 
Invasion assay
Invasion was assessed by the FATIMA assay (8) Spheroid volumes were calculated using the formula: (width 2 x length x 3.14)/6 (17). To assess cell viability, spheroids were incubated for 30 min with 2 µg/ml PI and then observed under laser fluorescence microscope (DMI 600013, Leica) (original magnification 4×). Single spheroids were incubated with 1:50 Lipoplatin-FITC (6) . Spheroid images were acquired using the confocal microscope (Leica DM IRE2) to trace the penetration of Lipoplatin-FITC.
Migration/dissemination (14) : this assay was performed in 96-well plates pre-coated with 10 μg/mL collagene I (Sigma Aldrich) and blocked with BSA (1 mg/mL) for 2 h. Pre-formed spheroids were layered (3-5 spheroids/well) in the 96-well plates in the absence or in the presence of Lipoplatin (25, 50 µM). Image analysis software was used to calculate the spheroid size. The extent of migration was determined using Adobe Photoshop by outlining the entire area of the dispersed cells (14) . The fold-change in area was calculated dividing the pixel area of the spheroid at 24 and 48 h by the pixel area at time 0.
Tumor xenograft experiments
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Software and statistical analysis of data
Values are presented as the mean with the standard error of not less than three measurements (unless otherwise stated) (mean ± SEM). To estimate the equal sample size for the mouse study groups, the experiment was designed to be able to detect a 0.60 difference with 0.90 power and a α error of 0.05. Statistical analysis was performed using GraphPad Prism 6 Software (GraphPad, San Diego, CA, USA). The statistical significance of differences was determined by Student's t-test for comparison between two groups.
Analysis of variances (ANOVA) was used to evaluate the correlation of data among three or more groups; consecutive multiple comparison analysis was performed using Dunnett's or Tukey's tests. Differences were considered statistically significant at P<0.05.
on October by the Annexin-V/PI staining (Fig. 1B) , the activation of caspases 9, 8, and 3 ( Fig. 1C ) and DNA fragmentation (Fig. 1D, left panels) . In analogy with Cisplatin (19) , Lipoplatin decreased the mitochondrial membrane potential (Fig. 1D, central panels) and induced Cyt-c release (Fig.   1D, right panels) . Lipoplatin increased the pro-apototic molecule Bax, decreased the antiapoptotic Bcl-2, and only slightly decreased Bcl-xL expression (Fig. 1E) . Lipoplatin increased ROS production ( Figs. 2A and B) and reduced the enzymatic activity of TrxR (Fig. 2C) , a selenoenzyme essential to maintain the cellular redox status and to protect against oxidative damage due to ROS accumulation (20) , in a dose-dependent manner in both cell lines.
In addition, we evaluated Lipoplatin activity in A2780 and its Cisplatin-resistant clone 
Lipoplatin synergized with Doxorubicin and Abraxane
The standard treatment of patients with advanced ovarian cancer is cytoreductive surgery followed by combination chemotherapy with taxanes or Doxorubicin and platinating agents (21, 22) . We evaluated if also the combination of Lipoplatin with Doxorubicin ( Table S1 ). Finally, the combination of Carboplatin with Doxorubicin exerted very low synergistic (OVCAR5) or additive (SKOV3) effects. In SKOV3 cells all the three taxanes exerted a significant synergistic activity, whereas in OVCAR5 only Paclitaxel displayed synergy (Supplementary Table S2 ).
Lipoplatin inhibited invasion and down-modulated EGFR expression
To exclude that a lower migration rate could be attributable to a decreased cell proliferation, cells were cultured for 72 h in the presence of less drug (10 μM) and at low serum concentration. Then, we evaluated cell invasion through a type I collagen-coated Boyden chamber. Already at 5 h, Lipoplatin decreased invasion of about 45% and 51% in OVCAR5 and SKOV3 cells, respectively (Fig. 3A) , and this level of inhibition was maintained at 24 h.
EGFR is usually over-expressed in ovarian carcinoma, and its activation is related not only to survival but also to invasion and metastasis (25). Both OVCAR5 and SKOV3 had similar invasive properties (Fig. 3A) and expressed high levels of EGFR (Figs. 3B and C) . Lipoplatin down-regulated in a dose-dependent manner EGFR expression (Figs. 3B and C) .
Lipoplatin reduced ALDH+ and CD133+ cells and inhibited both growth and migration of
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cells from pre-formed spheroids
Together with the ability to form spheroids (26), the enzymatic activity of ALDH and CD133 expression (27) Fig. S3A ), inhibited the spheroids growth (Figs. 5A and B) in a dosedependent manner. Lipoplatin increased the PI positive dead cells (Fig. 5C) . Consistently, we found that Lipoplatin-FITC deeply penetrated into spheroids (Fig. 5D) . Lipoplatin decreased the capability of SKOV3 cells to migrate/disseminate out of the spheroids with a 50% reduction of the area covered by migrating cells (Figs. 5E and F) .
Lipoplatin inhibited the growth of ovarian cancer xenografts
We analyzed the anticancer activity of Lipoplatin also in vivo. 
Discussion
Cisplatin is very effective for the treatment of ovarian cancers; however, its severe toxicity and the emergence of primary or acquired resistance limit its efficacy. In this study, we investigated the biological activity and molecular mechanisms of action of a new formulation of Cisplatin, Lipoplatin, the most clinically active formulation of liposomal encapsulated Cisplatin to date (3, 6) . 
also decrease tumor invasion and/or proliferation induced by EGFR activation. Since ovarian carcinoma has a very poor rate of survival and is characterized by the presence of diffuse peritoneal metastases (40) , this significant activity of Lipoplatin could also be useful in highly aggressive, poor-prognosis subgroup of high-grade malignant ovarian cancer characterized by the coexpression of ALDH/EGFR (41).
Together with the enzymatic activity of ALDH, the expression of CD133 is considered a marker of ovarian CSCs and is associated with drug resistance (27, 42, 43) . Accordingly, Lipoplatin reduced the percentage of ALDH+ and CD133+ cells, suggesting that Lipoplatin could eliminate ovarian CSCs that are more chemo-and radio-resistant than the bulk of tumor cells and likely responsible for tumor relapse, the major clinical problem in cancer treatment.
Ovarian cancer cells are present in ascitic fluids either as single cells or as less or more compact macro aggregates, the latter contributing most to the spreading to secondary sites (28) . In fact, these aggregates can travel through the ascitic fluid and attach to organs within the peritoneal cavity, a process that requires invasion of the mesothelial cell layer covering these organs (44) . The 3D in vitro growth conditions (spheroids) recall several characteristics of ovarian cancer ascites cellular macro aggregates, including resistance to Cisplatin, and represent a more reliable model than 2D cell cultures (45) . Moreover, the present finding that Lipoplatin inhibited the growth and the dissemination of cells from pre- 
